Autoimmune factor XIII deficiency with unusual laboratory and clinical phenotype

Abstract

Hemorrhagic diathesis due to anti‐factor XIII (FXIII) autoantibody is a rare but severe disorder. Challenges of the diagnosis and treatment is demonstrated by the case of a 67‐year‐old female without previous bleeding history, who suffered a huge muscular hematoma. Without blank subtraction 18% plasma FXIII activity was measured; however, after correction for blank the activity was below the limit of detection and the lack of fibrin cross‐linking in the patient's plasma confirmed the latter result. FXIII‐A2 antigen was not detectable by enzyme‐linked immunosorbent assay (ELISA); however, it was well detected by western blotting. The autoantibody showed high affinity toward FXIII‐A2. Its considerable inhibitory activity was demonstrated by high titer in Bethesda units and the low immunoglobulin G concentration required for inhibition. The main biochemical effect was the inhibition of Ca2+‐induced activation. Eradication therapy was only partially successful. Four months after the last hemorrhagic event the patient suffered deep vein thrombosis complicated by pulmonary embolism.

Iodoacetamide blank compensation in FXIII functional assays: Is it still necessary?

“…Vanessa Leguy-Seguin 2 Camille Chavy 3 Fabienne Genre-Volot 4 Anamaria Callegarin 4 Jean Amiral 5 Bernard Bonnotte 2,6 Thomas Lecompte 1,7 Emmanuel de Maistre Jean Amiral https://orcid.org/0000-0002-0680-9172…”

“…Plasma levels of FXIII were found low, 17-26 IU/dL. The discrepancy between the clinical and laboratory phenotypes led us to complete the exploration leading to the diagnosis of an anti-FXIII autoantibody 5 with no response to FXIII concentrate (Fibrogammin ® , CSL Behring).…”